D'Addato M, Curti T, Bertini D, Donini I, Ferrero R, Fiorani P, Pellegrino F, Vecchioni R, Visconti W, Zinicola N
Cattedra di Chirurgia Vascolare, Policlinico S. Orsola, Bologna, Italy.
Int Angiol. 1992 Apr-Jun;11(2):106-12.
To compare the effects of indobufen (INB) with those of ASA+dipyridamole (DP) on graft patency, 113 patients undergoing femoropopliteal bypass surgery were randomly and blindly assigned to treatment with INB 400 mg daily or with ASA 900 mg daily plus DP 225 mg daily. Treatment started 2 days before surgery and lasted for 12 months. All patients underwent two angiographic examinations: the first early after surgery (mean 6 days) and the second at the end of the study (mean 368 days). The 1 year cumulative patency rate for INB was 60% higher but not statistically different from the ASA-DP group (53.2%). The relative risk (INB/ASA+DP) calculated by the Mantel-Haenszel test was 0.86 (confidence limits 0.54-1.35). Only the site of operation (above-knee or below-knee) has a significant prognostic value on the fate of the graft.
